Targeted Therapy With Venetoclax and Daratumumab as Part of HSCT Preparative Regimen in Children With Chemorefractory Acute Myeloid Leukemia
Open Access
- 25 November 2022
- journal article
- research article
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 29 (2) , 127.e1-127.e9
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Education and Science of the Russian Federation (075-15-2020-807)
This publication has 42 references indexed in Scilit:
- Exploitation of natural killer cells for the treatment of acute leukemiaBlood, 2016
- Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trialThe Lancet, 2016
- Improved immune recovery after transplantation of TCRαβ/CD19-depleted allografts from haploidentical donors in pediatric patientsBone Marrow Transplantation, 2015
- Leukemia cell mobilization with G-CSF plus plerixafor during busulfan–fludarabine conditioning for allogeneic stem cell transplantationBone Marrow Transplantation, 2015
- NIH Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. The 2014 Pathology Working Group ReportTransplantation and Cellular Therapy, 2015
- The Prognostic Value of CXCR4 in Acute Myeloid LeukemiaApplied Immunohistochemistry & Molecular Morphology, 2013
- Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological TumorsThe Journal of Immunology, 2011
- Hematopoietic Stem-Cell Transplantation for Acute Leukemia in Relapse or Primary Induction FailureJournal of Clinical Oncology, 2010
- A large-scale method for the selective depletion of αβ T lymphocytes from PBSC for allogeneic transplantationCytotherapy, 2007
- Assessment of Bcl-2 Expression as Modulator of Fas Mediated Apoptosis in Acute LeukemiaHematology, 2004